

IMPROVING CARE & OUTCOMES



Interim Report 2009

Fisher & Paykel
HEALTHCARE

Our growth strategy remains consistent – expand our range of innovative products, develop opportunities to serve additional patient groups and increase our international presence.



Half Year Review

Our growth strategy remains consistent – expand our range of innovative products, develop opportunities to serve additional patient groups and increase our international presence. During the first half of the 2009 financial year we continued to make very encouraging progress against those objectives. We introduced a number of significant new products, increased our investment in research and development and continued to expand our international sales activities.


Profit after tax for the six months increased 51% to NZ\$28.3 million compared to NZ\$18.7 million for the same period last year. Operating profit grew 48% to NZ\$46.1 million compared to NZ\$31.2 million for the first half last year.

Operating revenue in NZ dollar terms increased 24% to NZ\$213.3 million for the six months. Expressed in US dollars, operating revenue grew a very encouraging 25% to US\$159.6 million, with particularly strong growth achieved in our respiratory and acute care product group.

Our operating revenue is generated in a variety of currencies, with our products sold in more than 110 countries in total. US dollars contributed 59% of operating revenue, Euros 23%, Australian dollars 8%, British pounds 5%, New Zealand dollars 1%, and other currencies 4%.

Currency exchange rates have continued to be very volatile. During the six months, the NZD:USD spot exchange rate ranged from 0.80 to 0.64 with an average spot rate of 0.7444, slightly above the average spot rate of 0.7427 for the same period last year.

Your directors have approved an interim dividend for the financial year ending 31 March 2009 of NZ 5.4 cents per ordinary share (2008: 5.4 cents), carrying full imputation credit. Non-resident shareholders will receive a supplementary dividend of NZ 0.953 cents per share. The interim dividend will be paid on 12 December 2008, with a record date of 3 December, and an ex-dividend date of 27 November for the ASX and 4 December for the NZSX.



OPERATING REVENUE BY PRODUCT GROUP

US DOLLARS Six Months Ended 30 September			NZ DOLLARS Six Months Ended 30 September			
Percentage variation	2007 US\$000	2008 US\$000	Product Group	2008 NZ\$000	2007 NZ\$000	Percentage variation
+36%	64,090	87,105	Respiratory & acute care	116,503	86,533	+35%
+14%	59,766	68,041	Obstructive sleep apnea	90,856	80,814	+12%
+25%	123,856	155,146	Core products subtotal	207,359	167,347	+24%
+15%	3,847	4,423	Distributed and other	5,912	5,201	+14%
+25%	\$127,703	\$159,569	Total	\$213,271	\$172,548	+24%

RESPIRATORY & ACUTE CARE

Our heated humidifier systems play an important role in improving patient care in the treatment of a variety of medical conditions which interfere with normal respiration. Warming and moistening of the gases delivered through mechanical ventilation or oxygen therapy helps to reproduce the normal functioning of the nose and upper airways and reduces airway moisture loss and the occurrence of adverse side effects.

Our devices include humidifier controllers, chambers, breathing circuits which convey medical gases to and from the patient, interfaces, oxygen therapy systems, neonatal resuscitators and warmers. We are also pioneering a humidification system which humidifies the cold, dry carbon dioxide gas which is used to inflate the patient's abdomen during 'keyhole' or laparoscopic surgery.

Demand for our respiratory humidification devices was particularly robust during the six months and contributed to respiratory and acute care operating revenue of US\$87.1 million, up 36% on the same period last year.

We have previously outlined the opportunities we were pursuing to increase the number of patients our devices can assist, by expanding from our traditional intensive care ventilation market into non-invasive ventilation, oxygen therapy, humidity therapy, neonatal respiratory care and surgery. We continued to make very encouraging progress, with revenue from those new applications growing strongly.

Recently we began to make our technology available to even more respiratory patients with the introduction of our new PT100 humidity therapy device, which has application in the hospital as well as the home. This device has been designed to provide humidity therapy and to assist with the treatment of patients with chronic obstructive pulmonary disease, or COPD.

OBSTRUCTIVE SLEEP APNEA

Most people with OSA do not realise that they have a condition which causes excessive daytime fatigue, is associated with cardiovascular disease, strokes and diabetes, and is directly linked to hypertension. In fact, tens of millions of people worldwide who have untreated OSA stop breathing for short periods many times each night while they are asleep.

Continuous positive airway pressure, or CPAP, therapy is the most common treatment for OSA. CPAP therapy prevents the collapse and blockage of the airway during periods of deep sleep and is delivered using an air flow generator, humidifier, tubing and mask.

For our OSA product group, operating revenue grew 14% to US\$68.0 million for the six months. We continued to expand our CPAP flow generator and mask offering for the treatment of obstructive sleep apnea and have recently introduced a new premium CPAP flow generator range and two new masks.

The new SleepStyle 240 CPAP flow generators are able to collect data during treatment onto a removable USB SmartStick flash memory device which may be conveniently reviewed by the patient's physician without the need for any special card-reading hardware. The ability to provide efficacy reporting and removable data storage media opens up a new product category for us. The SleepStyle 240 broadens our premium flow generator device offering alongside our SleepStyle Auto flow generator.

The innovative design of our new Zest nasal mask combines a new Easy-Clip silicone seal with our previously proven FlexiFit and Glider technology. The Zest is small and quiet and is designed to fit most patients straight out of the box. Our new Forma full face mask offers enhanced comfort with a greater range of movement due to its new FlexiFoam cushion. The cushion is soft and light and features advanced active contouring that conforms naturally to the patient's face.

INTERNATIONAL SALES

North America generated 46% of our operating revenue for the half year, with Europe contributing 32% and Asia/Pacific and Other 22%. Our products are sold in more than 110 countries around the world.

We have continued to expand our international sales, marketing and operations teams to increase our geographical coverage and to support ongoing growth. We have our own sales offices or sales support staff located in 26 countries.


RESEARCH AND DEVELOPMENT

Investment in research and development continues to be fundamental to increasing our opportunities for growth and to ensuring that we can offer devices which can improve patient care and outcomes.

Our research and development expenditure grew 16% compared with the same period last year to NZ\$13.3 million, representing 6.2% of operating revenue. We have already introduced a number of new products this year and have a substantial new product pipeline under development which includes additional masks, breathing system consumables and flow generators.

OUTLOOK

Our performance in the six months to 30 September 2008, coupled with the introduction of new products and growth in our international sales activities, gives us confidence that we can achieve continuing strong revenue and earnings growth for the full year.



GARY PAYKEL
Chairman



MICHAEL DANIELL
Managing Director and
Chief Executive Officer



PricewaterhouseCoopers
188 Quay Street
Private Bag 92162
Auckland, New Zealand
DX CP24073
www.pwc.com/nz
Telephone +64 9 355 8000
Facsimile +64 9 355 8001

Accountants' Report

To the shareholders of Fisher & Paykel Healthcare Corporation Limited

We have reviewed the interim consolidated financial statements on pages 6 to 15. The interim consolidated financial statements provide information about the past financial performance and cash flows of the Group for the period ended 30 September 2008 and its financial position as at that date. This information is stated in accordance with the accounting policies set out on page 10.

Directors' responsibilities

The Company's Directors are responsible for the preparation and presentation of the interim consolidated financial statements that present fairly the financial position of the Group as at 30 September 2008 and its financial performance and cash flows for the period ended on that date.

Independent Accountants' responsibilities

We are responsible for reviewing the interim consolidated financial statements presented by the Directors in order to report to you whether, in our opinion and on the basis of the procedures performed by us, anything has come to our attention that would indicate that the interim consolidated financial statements do not present fairly the matters to which they relate.

This report is made solely to the Company's shareholders, as a body, in accordance with our engagement terms. Our review has been undertaken so that we might state to the Company's shareholders those matters we are required to state to them in an independent accountants' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's shareholders as a body, for our review, for this report, or for the opinions we have formed.

Basis of opinion

A review is limited primarily to enquiries of company personnel and analytical review procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit on the interim consolidated financial statements and, accordingly, we do not express an audit opinion.

We have reviewed the interim consolidated financial statements of the Group for the period ended 30 September 2008 in accordance with the Review Engagement Standards issued by the Institute of Chartered Accountants of New Zealand.

We have no relationship with or interests in the Company or any of its subsidiaries other than in our capacity as accountants conducting this review, auditors of the annual financial statements and providers of other assurance related services.



Accountants' Report

Fisher & Paykel Healthcare Corporation Limited

Review opinion

We have reviewed the financial performance and cash flows of the Group for the six month period ended 30 September 2008 and its financial position as at that date.

Based on our review, nothing has come to our attention that causes us to believe that the interim consolidated financial statements do not present fairly the financial position of the Group as at 30 September 2008 and its financial performance and cash flows for the period ended on that date, in accordance with both International Accounting Standard 34 and New Zealand Equivalent to International Accounting Standard 34, Interim Financial Reporting.

Our review was completed on 20 November 2008 and our review opinion is expressed as at that date.

A handwritten signature in blue ink that reads "PricewaterhouseCoopers".

Chartered Accountants

Auckland

CONSOLIDATED INCOME STATEMENTS

	Notes	Unaudited Six Months Ended 30 September 2008 NZ\$000	Unaudited Six Months Ended 30 September 2007 NZ\$000
Operating revenue	3	213,271	172,548
Cost of sales		(95,188)	(80,068)
Gross profit		118,083	92,480
Other income	4	1,500	-
Selling, general and administrative expenses		(60,224)	(49,838)
Research and development expenses		(13,308)	(11,456)
Operating profit before financing costs		46,051	31,186
Financing income		980	22
Financing expense		(3,877)	(2,242)
Exchange gain (loss) on foreign currency borrowings		(3,355)	798
Net financing expenses		(6,252)	(1,422)
Profit before tax	5	39,799	29,764
Tax expense	6	(11,536)	(11,068)
Profit after tax		28,263	18,696
Basic earnings per share		5.5 cps	3.7 cps
Diluted earnings per share		5.4 cps	3.6 cps
Weighted average basic ordinary shares outstanding		509,465,471	510,032,719
Weighted average diluted ordinary shares outstanding		525,826,551	525,025,490

CONSOLIDATED BALANCE SHEETS

	Notes	Unaudited 30 September 2008 NZ\$000	Unaudited 30 September 2007 NZ\$000	Audited 31 March 2008 NZ\$000
ASSETS				
Current assets				
Cash and cash equivalents		8,700	4,611	5,263
Trade and other receivables	7	74,213	58,570	60,262
Inventories	8	62,478	54,677	50,770
Derivative financial instruments	16	1,535	4,921	3,311
Tax receivable		3,657	6,424	9,968
Total current assets		150,583	129,203	129,574
Non-current assets				
Property, plant and equipment		189,033	188,249	186,489
Intangible assets		4,203	4,498	4,287
Other receivables	7	1,551	843	915
Derivative financial instruments	16	2,654	2,940	1,685
Deferred tax asset		11,701	7,641	8,717
Total assets		359,725	333,374	331,667
LIABILITIES				
Current liabilities				
Interest-bearing liabilities	9	59,184	80,841	65,007
Trade and other payables	10	50,868	37,298	41,550
Provisions		2,274	1,680	2,342
Tax payable		1,159	667	640
Derivative financial instruments	16	5,298	139	842
Total current liabilities		118,783	120,625	110,381
Non-current liabilities				
Interest-bearing liabilities	9	49,472	-	21,107
Provisions		967	490	640
Other payables	10	3,677	3,453	2,720
Derivative financial instruments	16	727	4	1,155
Total liabilities		173,626	124,572	136,003
EQUITY				
Share capital		6,154	3,819	6,083
Treasury shares		(2,392)	(1,701)	(2,436)
Retained earnings		181,269	199,356	188,668
Cash flow hedge reserve		(1,714)	4,713	905
Employee share entitlement reserve		241	407	184
Employee share option reserve		2,541	2,208	2,260
Total equity		186,099	208,802	195,664
Total liabilities and equity		359,725	333,374	331,667

On behalf of the Board
20 November 2008



G A Paykel
Chairman



M G Daniell
Managing Director and
Chief Executive Officer

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Unaudited Six Months Ended 30 September 2008 NZ\$000	Unaudited Six Months Ended 30 September 2007 NZ\$000	Audited Year Ended 31 March 2008 NZ\$000
Total equity at beginning of the period	195,664	236,547	236,547
Movement in cash flow hedge reserve, net of tax	(2,619)	952	(2,856)
Profit after tax	28,263	18,696	35,276
Total recognised income and expense for the period	25,644	19,648	32,420
Dividends paid	(35,662)	(35,775)	(63,250)
Issue of share capital	56	124	2,106
Repurchase of share capital	-	(12,252)	(12,252)
Movement in employee share entitlement reserve	57	89	(134)
Movement in employee share option reserve	281	214	266
Movement in treasury shares	44	-	(735)
Share options issued for employee services	1	186	514
Employee share scheme shares issued for employee services	14	21	182
Total equity at end of the period	186,099	208,802	195,664

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Notes	Unaudited Six Months Ended 30 September 2008 NZ\$000	Unaudited Six Months Ended 30 September 2007 NZ\$000
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		205,352	173,255
Dividends received		5	4
Interest received		938	24
Payments to suppliers and employees		(169,436)	(149,890)
Tax paid		(4,370)	(7,068)
Interest paid		(3,030)	(2,184)
Net cash flows from operations	15	29,459	14,141
CASH FLOWS (USED IN) INVESTING ACTIVITIES			
Sale of property, plant and equipment		2	13
Purchase of property, plant and equipment		(8,296)	(7,019)
Purchase of intangible assets		(813)	(460)
Net cash flows (used in) investing activities		(9,107)	(7,466)
CASH FLOWS (USED IN) FINANCING ACTIVITIES			
Employee share purchase schemes		338	271
Issue of share capital		56	124
Repurchase of share capital		-	(12,252)
New borrowings		42,642	39,486
Repayment of borrowings		(24,794)	-
Dividends paid		(35,662)	(35,775)
Supplementary dividends paid to overseas shareholders		(1,229)	(2,719)
Net cash flows (used in) financing activities		(18,649)	(10,865)
Net increase (decrease) in cash		1,703	(4,190)
Opening cash		(3,294)	2,283
Effect of foreign exchange rates		463	(248)
Closing cash		(1,128)	(2,155)
RECONCILIATION OF CLOSING CASH			
Cash and cash equivalents		8,700	4,611
Bank overdrafts	9	(9,828)	(6,766)
		(1,128)	(2,155)

NOTES TO THE FINANCIAL STATEMENTS

For the six months ended 30 September 2008

1. GENERAL INFORMATION

Fisher & Paykel Healthcare Corporation Limited (the “Company”) together with its subsidiaries (the “Group”) is a leading designer, manufacturer and marketer of medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. Products are sold in over 110 countries worldwide.

The Company is a limited liability company incorporated and domiciled in New Zealand. The address of its registered office is 15 Maurice Paykel Place, East Tamaki, Auckland. The Company is registered under the Companies Act 1993 and is an issuer for the purposes of the Financial Reporting Act 1993.

These consolidated interim financial statements were approved for issue by the Board of Directors on 20 November 2008, and have been reviewed, not audited.

2. BASIS OF PREPARATION OF FINANCIAL STATEMENTS

These general purpose financial statements for the six months ended 30 September 2008 have been prepared in accordance with NZ IAS 34, *Interim Financial Reporting*.

These consolidated interim financial statements do not include all the notes of the type normally included in an annual financial report. Accordingly, this report should be read in conjunction with the audited financial statements for the year ended 31 March 2008, which have been prepared in accordance with International Financial Reporting Standards (IFRS).

All significant accounting policies have been applied on a basis consistent with those used in the audited financial statements for the year ended 31 March 2008.

3. OPERATING REVENUE

Revenue before hedging:

North America
Europe
Asia Pacific
Other

Total revenue before hedging

Foreign exchange gain (loss) on hedged sales

Total operating revenue

Six Months Ended 30 September 2008 NZ\$000	Six Months Ended 30 September 2007 NZ\$000
--	--

99,488	77,617
68,883	53,208
34,960	28,661
11,913	7,957

215,244	167,443
----------------	---------

(1,973)	5,105
----------------	-------

213,271	172,548
----------------	---------

4. OTHER INCOME

Research and development tax credit

1,500	-
--------------	---

5. EXPENSES

Profit before tax includes the following expenses:

Depreciation

7,131	6,679
--------------	-------

Amortisation:

Patents and trademarks
Software

464	610
------------	-----

414	317
------------	-----

Total amortisation

878	927
------------	-----

Employee benefits expense

69,980	53,687
---------------	--------

Rental expense

1,298	1,136
--------------	-------

Bad debts written off

147	201
------------	-----

Movement in provision for doubtful debts

308	(18)
------------	------

6. TAX EXPENSE

	Six Months Ended 30 September 2008 NZ\$000	Six Months Ended 30 September 2007 NZ\$000
Profit before tax	39,799	29,764
Tax expense at the New Zealand rate of 30% (2007: 33%)	11,940	9,822
Adjustments to tax for:		
Research and development tax credit	(450)	-
Non-assessable income	(67)	(67)
Non-deductible expenses	429	328
Foreign income tax rates other than 30% (2007: 33%)	459	74
Effect of foreign currency translation	(1,078)	421
This year's tax	11,233	10,578
Release of deferred tax asset due to reduction in income tax rate	-	156
Other	303	334
Tax expense	11,536	11,068

7. TRADE AND OTHER RECEIVABLES

CURRENT

	30 September 2008 NZ\$000	30 September 2007 NZ\$000	31 March 2008 NZ\$000
Trade receivables	67,855	53,403	57,239
Less allowance for doubtful trade receivables	(1,068)	(765)	(760)
	66,787	52,638	56,479
Other receivables	7,426	5,932	3,783
	74,213	58,570	60,262

NON-CURRENT

Other receivables	1,551	843	915
-------------------	-------	-----	-----

8. INVENTORIES

Materials	15,360	14,169	15,397
Finished products	50,468	43,056	37,905
Provision for obsolescence	(3,350)	(2,548)	(2,532)
	62,478	54,677	50,770

9. INTEREST-BEARING LIABILITIES

CURRENT

Bank overdrafts	9,828	6,766	8,557
Borrowings	49,356	74,075	56,450
	59,184	80,841	65,007

NON-CURRENT

Borrowings	49,472	-	21,107
------------	--------	---	--------

NOTES TO THE FINANCIAL STATEMENTS

For the six months ended 30 September 2008

	30 September 2008 NZ\$000	30 September 2007 NZ\$000	31 March 2008 NZ\$000
10. TRADE AND OTHER PAYABLES			
CURRENT			
Trade payables	21,823	15,945	14,660
Employee entitlements	14,362	12,985	11,945
Other payables and accruals	14,683	8,368	14,945
	50,868	37,298	41,550
NON-CURRENT			
Employee entitlements	3,084	2,837	2,141
Other payables and accruals	593	616	579
	3,677	3,453	2,720

11. RELATED PARTY TRANSACTIONS

During the period the Group has not entered into any material contracts involving related parties or directors' interests. No amounts owed by related parties have been written off or forgiven during the period.

During the period the Company advanced and repaid loans to its subsidiaries by way of internal current accounts. In presenting the financial statements of the Group, the effect of transactions and balances between fellow subsidiaries and those with the Company have been eliminated. All transactions with related parties were in the normal course of business and provided on commercial terms.

The following Directors received directors fees and dividends in relation to shares in which they had a beneficial interest as detailed below:

	Six Months Ended 30 September 2008		Six Months Ended 30 September 2007	
	Directors fees NZ\$000	Dividends NZ\$000	Directors fees NZ\$000	Dividends NZ\$000
Non-executive directors				
Sir Colin Maiden	52	4	47	4
Gary Paykel	86	177	78	177
Nigel Evans	48	2	43	2
Michael Smith	71	14	65	14
Lindsay Gillanders	38	36	35	36
Arthur Morris	38	-	-	-
Adrienne Clarke*	-	-	40	4
Executive director				
Michael Daniell	-	51	-	51

*Adrienne Clarke resigned as a director on 20 February 2008.

12. CAPITAL EXPENDITURE COMMITMENTS

Capital expenditure commitments contracted for but not recognised as at the reporting date

30 September 2008 NZ\$000	30 September 2007 NZ\$000	31 March 2008 NZ\$000
3,770	1,861	1,544

13. OPERATING LEASE COMMITMENTS

Gross commitments under non-cancellable operating leases for the Group:

	30 September 2008 NZ\$000	30 September 2007 NZ\$000	31 March 2008 NZ\$000
Within one year	4,223	3,073	4,054
Between one and two years	2,991	2,448	2,902
Between two and five years	2,264	3,502	2,916
Over five years			
	9,478	9,023	9,872

Operating lease commitments relate mainly to occupancy leasing of buildings.

14. CONTINGENT LIABILITIES

Periodically the Group is party to litigation including product liability and patent claims. To date such claims have been few in number and have been expensed or covered by our insurance. The Directors are unaware of the existence of any claim or other contingencies that would have a material impact on the operations of the Group.

Where the Company enters into financial guarantee contracts to guarantee the indebtedness of other companies within the Group, the Company considers these to be insurance arrangements, and accounts for them as such. In this respect, the Company treats the guarantee contract as a contingent liability until such time as it becomes probable that the Company will be required to make a payment under the guarantee.

The Company has a contingent liability relating to guarantees of subsidiary company indebtedness.

15. CASH FLOW RECONCILIATIONS

	Six Months Ended 30 September 2008 NZ\$000	Six Months Ended 30 September 2007 NZ\$000
Profit after tax	28,263	18,696
Add (deduct) non-cash items:		
Depreciation and writedown of property, plant and equipment to recoverable amount	7,131	6,679
Amortisation of intangibles	878	927
Accrued financing income / expense	824	(33)
Movement in provisions	259	330
Movement in deferred tax asset	(1,861)	2,354
Movement in working capital:		
Trade and other payables	12,201	(5,705)
Trade and other receivables	(14,587)	(2,621)
Inventory	(11,708)	(7,980)
Provision for taxation net of supplementary dividend paid	8,059	1,494
Net cash flows from operations	29,459	14,141

NOTES TO THE FINANCIAL STATEMENTS

For the six months ended 30 September 2008

16. DERIVATIVE FINANCIAL INSTRUMENTS

	30 September 2008		30 September 2007		31 March 2008	
	Assets NZ\$000	Liabilities NZ\$000	Assets NZ\$000	Liabilities NZ\$000	Assets NZ\$000	Liabilities NZ\$000
CURRENT						
Foreign currency forward exchange contracts	1,147	501	2,840	134	958	358
Foreign currency option contracts	388	4,797	2,081	5	2,338	484
Interest rate swaptions	-	-	-	-	15	-
	1,535	5,298	4,921	139	3,311	842
NON-CURRENT						
Foreign currency forward exchange contracts	2,562	91	2,940	-	1,604	99
Foreign currency option contracts	92	33	-	4	81	86
Interest rate swaps	-	603	-	-	-	970
	2,654	727	2,940	4	1,685	1,155

Notional principal amounts of forward exchange and option contracts outstanding were as follows:

	30 September 2008 NZ\$000	30 September 2007 NZ\$000	31 March 2008 NZ\$000
Purchase commitments forward exchange contracts	1,746	1,414	1,902
Sale commitments forward exchange contracts	162,181	88,230	87,490
NZD call option contracts purchased	7,913	65,225	40,655
Collar option contracts - NZD call option purchased (i)	126,958	19,507	63,279
Collar option contracts - NZD call option sold (i)	139,484	21,405	70,030

(i) Foreign currency notional principal amounts are equal.

Foreign currency principal amounts hedged in relation to sale commitments were as follows:

	30 September 2008 000s	Foreign Currency 30 September 2007 000s	31 March 2008 000s
USD	US\$75,500	US\$61,100	US\$59,500
EUR	€72,430	€31,910	€42,860
GBP	£2,000	£2,785	£2,275
AUD	A\$6,200	A\$5,300	A\$3,250
CAD	C\$11,650	C\$7,325	C\$9,275
CHF	SFr675	-	SFr760
SEK	kr4,000	-	kr5,000

Foreign currency principal amounts hedged in relation to purchase commitments were as follows:

EUR	€200	-	€300
JPY	¥106,000	¥110,000	¥110,000

Notional principal amounts of interest rate derivative contracts outstanding were as follows:

	30 September 2008 NZ\$000	30 September 2007 NZ\$000	31 March 2008 NZ\$000
Interest rate swaps	52,368	-	19,009
Interest rate swaptions	10,000	-	10,000

The interest rate swaps have terms of up to 10 years. All interest rate swaptions will expire during the 2009 financial year.

17. SEGMENTS

a. Primary segment - business

The Group operates in one business segment, being the design, manufacture and marketing of medical devices.

b. Secondary segment - geographical

A geographical segment is engaged in providing products or services within a particular economic environment and is subject to risks and returns that are different from those of segments operating in other economic environments.

Segment:	Operating revenue Six months ended		Total assets As at		Capital expenditure Six months ended	
	30 September 2008 NZ\$000	30 September 2007 NZ\$000	30 September 2008 NZ\$000	30 September 2007 NZ\$000	30 September 2008 NZ\$000	30 September 2007 NZ\$000
North America	97,937	80,236	60,216	45,106	24	130
Europe	68,834	54,921	42,123	30,279	63	148
Asia Pacific	34,782	29,160	257,293	257,943	8,170	6,709
Other	11,718	8,231	93	46	39	32
	213,271	172,548	359,725	333,374	8,296	7,019

In presenting the information on geographical segments, segment revenue is based on the geographical location of customers. Segment assets are based on the geographical location of the assets.

18. SIGNIFICANT EVENTS AFTER BALANCE DATE

On 20 November 2008 the directors approved the payment of a fully imputed 2009 interim dividend of \$27,513,358 (5.4 cents per share) to be paid on 12 December 2008.

GROUP STRUCTURE

* FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED OWNS:

- * Fisher & Paykel Healthcare Limited (NZ)
- * Fisher & Paykel Healthcare Pty Limited (Australia)
- * Fisher & Paykel Healthcare Treasury Limited (NZ)
- Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited (NZ)
- Fisher & Paykel Healthcare Limited (UK)
- Fisher & Paykel Holdings Inc. (USA)
- Fisher & Paykel do Brasil Ltda (Brazil)
- Fisher & Paykel Healthcare (Guangzhou) Limited (China)
- Fisher & Paykel Healthcare Asia Limited (NZ)

FISHER & PAYKEL HEALTHCARE LIMITED (NZ) OWNS:

- * Fisher & Paykel Healthcare Properties Limited (NZ)

FISHER & PAYKEL HOLDINGS INC. (USA) OWNS:

- Fisher & Paykel Healthcare Inc. (USA)

FISHER & PAYKEL HEALTHCARE LIMITED (UK) OWNS:

- Fisher & Paykel Healthcare SAS (France)
- Fisher & Paykel Holdings GmbH (Germany)
- Fisher & Paykel Healthcare AB (Sweden)

FISHER & PAYKEL HOLDINGS GMBH (GERMANY) OWNS:

- Fisher & Paykel Healthcare GmbH & Co KG (Germany)

FISHER & PAYKEL HEALTHCARE ASIA LIMITED (NZ) OWNS:

- Fisher & Paykel Healthcare Asia Investments Limited (NZ)

FISHER & PAYKEL HEALTHCARE ASIA INVESTMENTS LIMITED (NZ) OWNS:

- Fisher & Paykel Healthcare India Private Limited (India)
- Fisher & Paykel Healthcare K.K. (Japan)
- Fisher & Paykel Healthcare Limited (Hong Kong)

ALL COMPANIES ARE WHOLLY OWNED

- * COMPANIES OPERATING UNDER A NEGATIVE PLEDGE DEED

DIRECTORS' DETAILS

The Directors of Fisher & Paykel Healthcare Corporation Limited at any time during or since the end of the year are as follows:

Gary Albert Paykel	Chairman, Non-Executive, Independent
Michael Grenfell Daniell	Managing Director and Chief Executive Officer
Philip Michael Smith	Deputy Chairman, Non-Executive, Independent
Sir Colin James Maiden	Non-Executive, Independent
Dr Nigel Thomas Evans	Non-Executive, Independent
William Lindsay Gillanders	Non-Executive, Independent
Dr Arthur James Morris	Non-Executive, Independent

During the six months to 30 September 2008:

At the Annual Meeting of Shareholders held on 22 August 2008 Messrs Paykel and Smith retired by rotation, and Dr Morris retired, in accordance with the Company's constitution, and were re-elected to the Board.

EXECUTIVE'S DETAILS

Michael Daniell, Managing Director and Chief Executive Officer

SENIOR MANAGEMENT

Lewis Gradon, Senior Vice-President – Research and Development

Paul Shearer, Senior Vice-President – Sales and Marketing

Tony Barclay, Chief Financial Officer and Company Secretary

DIRECTORY

The details of the Company's principal administrative and registered office in New Zealand are:

15 Maurice Paykel Place, East Tamaki, Auckland 2013, New Zealand
 Telephone: +64-9-574 0100
 Facsimile: +64-9-574 0158
 Postal address: PO Box 14348, Panmure, Auckland 1741,
 New Zealand
 Internet address: www.fphcare.co.nz
 Email address: investor@fphcare.co.nz

SHARE REGISTRY

In New Zealand:
 Computershare Investor Services Limited
 Level 2, 159 Hurstmere Road, Takapuna, Auckland
 Postal address: Private Bag 92119, Auckland 1142,
 New Zealand
 Telephone: +64-9-488 8700
 Facsimile: +64-9-488 8787
 Investor enquiries: +64-9-488 8777
 Internet address: www.computershare.co.nz
 Email: enquiry@computershare.co.nz

STOCK EXCHANGES

The Company's ordinary shares are listed on the NZSX and the ASX.

INCORPORATION

The Company was incorporated in Auckland, New Zealand.

The details of the Company's registered office in Australia are:

36-40 New Street, Ringwood, Victoria 3134, Australia
 Telephone: +61-3-9879 5022
 Facsimile: +61-3-9879 5232
 Postal address: PO Box 167, Ringwood, Victoria 3134,
 Australia

In Australia:
 Computershare Investor Services Limited
 Level 4, 60 Carrington Street, Sydney, NSW 2000
 Postal address: GPO Box 7045, Sydney, NSW 1115,
 Australia
 Telephone: +61-2-8234 5000
 Facsimile: +61-2-8234 5050
 Investor enquires: 1 300 855 080 (for use within Australia only)
 Internet address: www.computershare.com.au
 Email: sydney.services@computershare.com.au

Fisher & Paykel
HEALTHCARE

